Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average Target Price from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received an average recommendation of "Buy" from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.71.

HUMA has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Humacyte in a report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. Wall Street Zen downgraded Humacyte from a "hold" rating to a "sell" rating in a report on Saturday. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Humacyte in a report on Monday, June 9th. Finally, Benchmark decreased their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Humacyte Price Performance

Shares of Humacyte stock traded down $0.04 on Thursday, reaching $2.37. 2,720,709 shares of the company were exchanged, compared to its average volume of 3,867,467. Humacyte has a 1-year low of $1.15 and a 1-year high of $9.79. The company has a market cap of $367.63 million, a P/E ratio of -1.77 and a beta of 2.00. The stock's 50 day moving average price is $1.91 and its 200-day moving average price is $3.15.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. On average, research analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. This represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 83,993 shares of company stock valued at $118,224. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Integrity Alliance LLC. purchased a new position in Humacyte in the first quarter worth $112,000. Woodline Partners LP raised its position in Humacyte by 38.7% in the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company's stock worth $6,735,000 after acquiring an additional 1,101,198 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in Humacyte in the first quarter worth $852,000. RA Capital Management L.P. purchased a new position in Humacyte in the first quarter worth $5,648,000. Finally, Kodai Capital Management LP purchased a new position in Humacyte in the first quarter worth $124,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.